Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Schwannomatosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Neurilemmoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Cytokine Release Syndrome 1Chronic Pain 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 49fludarabine 33Methotrexate 24blinatumomab 20fludarabine phosphate 19Dexamethasone 19Vincristine 18Whole-Body Irradiation 17Specimen Handling 16Cytarabine 16Tacrolimus 14Peripheral Blood Stem Cell Transplantation 14Mycophenolic Acid 14Melphalan 13Mercaptopurine 12Calcium Dobesilate 12merphos 11Busulfan 11Biopsy 11Magnetic Resonance Spectroscopy 10Etoposide 10Stem Cell Transplantation 9Prednisone 9Granulocyte Colony-Stimulating Factor 9Cyclosporine 9Thiotepa 8Rituximab 8Mesna 8Filgrastim 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × siltuximab × 90 days × Clear all
NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

University of Alabama at Birmingham

Phase 2 Completed
24 enrolled 8 charts
LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡